230 related articles for article (PubMed ID: 28809443)
1. Characterisation, in-vitro and in-vivo evaluation of valproic acid-loaded nanoemulsion for improved brain bioavailability.
Tan SF; Kirby BP; Stanslas J; Basri HB
J Pharm Pharmacol; 2017 Nov; 69(11):1447-1457. PubMed ID: 28809443
[TBL] [Abstract][Full Text] [Related]
2. Nanoemulsion-based Parenteral Drug Delivery System of Carbamazepine: Preparation, Characterization, Stability Evaluation and Blood-Brain Pharmacokinetics.
Tan SL; Stanslas J; Basri M; Abedi Karjiban RA; Kirby BP; Sani D; Basri HB
Curr Drug Deliv; 2015; 12(6):795-804. PubMed ID: 26324229
[TBL] [Abstract][Full Text] [Related]
3. Development of nanoemulsion for efficient brain parenteral delivery of cefuroxime: designs, characterizations, and pharmacokinetics.
Harun SN; Nordin SA; Gani SSA; Shamsuddin AF; Basri M; Basri HB
Int J Nanomedicine; 2018; 13():2571-2584. PubMed ID: 29731632
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the transport of valproic acid through the blood-brain barrier in rats by the Gastrodia elata extracts.
Yang L; Lin IH; Ting CT; Tsai TH
J Ethnopharmacol; 2021 Oct; 278():114276. PubMed ID: 34082013
[TBL] [Abstract][Full Text] [Related]
5. Panipenem, a carbapenem antibiotic, enhances the glucuronidation of intravenously administered valproic acid in rats.
Yamamura N; Imura K; Naganuma H; Nishimura K
Drug Metab Dispos; 1999 Jun; 27(6):724-30. PubMed ID: 10348803
[TBL] [Abstract][Full Text] [Related]
6. Ultrasonic emulsification of parenteral valproic acid-loaded nanoemulsion with response surface methodology and evaluation of its stability.
Tan SF; Masoumi HR; Karjiban RA; Stanslas J; Kirby BP; Basri M; Basri HB
Ultrason Sonochem; 2016 Mar; 29():299-308. PubMed ID: 26585010
[TBL] [Abstract][Full Text] [Related]
7. Brain delivery of valproic acid via intranasal administration of nanostructured lipid carriers: in vivo pharmacodynamic studies using rat electroshock model.
Eskandari S; Varshosaz J; Minaiyan M; Tabbakhian M
Int J Nanomedicine; 2011; 6():363-71. PubMed ID: 21499426
[TBL] [Abstract][Full Text] [Related]
8. Effects of amoxicillin/clavulanic acid on the pharmacokinetics of valproic acid.
Lee SY; Huh W; Jung JA; Yoo HM; Ko JW; Kim JR
Drug Des Devel Ther; 2015; 9():4559-63. PubMed ID: 26309401
[TBL] [Abstract][Full Text] [Related]
9. Investigation of low levels of plasma valproic acid concentration following simultaneous administration of sodium valproate and rizatriptan benzoate.
Hokama N; Hobara N; Kameya H; Ohshiro S; Hobara N; Sakanashi M
J Pharm Pharmacol; 2007 Mar; 59(3):383-6. PubMed ID: 17331341
[TBL] [Abstract][Full Text] [Related]
10. Increased erythrocyte distribution of valproic acid in pharmacokinetic interaction with carbapenem antibiotics in rat and human.
Omoda K; Murakami T; Yumoto R; Nagai J; Maeda Y; Kiribayashi Y; Takano M
J Pharm Sci; 2005 Aug; 94(8):1685-93. PubMed ID: 15986463
[TBL] [Abstract][Full Text] [Related]
11. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
Dutta S; Reed RC
Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
[TBL] [Abstract][Full Text] [Related]
12. Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure.
Gynther M; Peura L; Vernerová M; Leppänen J; Kärkkäinen J; Lehtonen M; Rautio J; Huttunen KM
Neurochem Res; 2016 Oct; 41(10):2797-2809. PubMed ID: 27412117
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modeling of disposition and drug-drug interactions for valproic acid and divalproex.
Conner TM; Nikolian VC; Georgoff PE; Pai MP; Alam HB; Sun D; Reed RC; Zhang T
Eur J Pharm Sci; 2018 Jan; 111():465-481. PubMed ID: 29030176
[TBL] [Abstract][Full Text] [Related]
14. Disposition of valpromide, valproic acid, and valnoctamide in the brain, liver, plasma, and urine of rats.
Blotnik S; Bergman F; Bialer M
Drug Metab Dispos; 1996 May; 24(5):560-4. PubMed ID: 8723737
[TBL] [Abstract][Full Text] [Related]
15. The relationship between glucuronide conjugate levels and hepatotoxicity after oral administration of valproic acid.
Lee MS; Lee YJ; Kim BJ; Shin KJ; Chung BC; Baek DJ; Jung BH
Arch Pharm Res; 2009 Jul; 32(7):1029-35. PubMed ID: 19641884
[TBL] [Abstract][Full Text] [Related]
16. Effect of cholestyramine resin on single dose valproate pharmacokinetics.
Malloy MJ; Ravis WR; Pennell AT; Diskin CJ
Int J Clin Pharmacol Ther; 1996 May; 34(5):208-11. PubMed ID: 8738857
[TBL] [Abstract][Full Text] [Related]
17. Development of Morin-Loaded Nanoemulsions Containing Various Polymers; Role of Polymers in Formulation Properties and Bioavailability.
Ikeuchi-Takahashi Y; Murata S; Murata W; Kobayashi A; Ishihara C; Onishi H
AAPS PharmSciTech; 2020 May; 21(5):150. PubMed ID: 32435858
[TBL] [Abstract][Full Text] [Related]
18. Nanoemulsion-based intranasal drug delivery system of saquinavir mesylate for brain targeting.
Mahajan HS; Mahajan MS; Nerkar PP; Agrawal A
Drug Deliv; 2014 Mar; 21(2):148-54. PubMed ID: 24128122
[TBL] [Abstract][Full Text] [Related]
19. A Chinese herb formula decreases the monocarboxylate transporter-mediated absorption of valproic acid in rats.
Yu CP; Tsai SY; Kao LJ; Chao PD; Hou YC
Phytomedicine; 2013 May; 20(7):648-53. PubMed ID: 23462213
[TBL] [Abstract][Full Text] [Related]
20. Eicosapentaenoic acid ablates valproate-induced liver oxidative stress and cellular derangement without altering its clearance rate: dynamic synergy and therapeutic utility.
El-Mowafy AM; Abdel-Dayem MA; Abdel-Aziz A; El-Azab MF; Said SA
Biochim Biophys Acta; 2011; 1811(7-8):460-7. PubMed ID: 21571092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
